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Animal models, human observational and genetic studies have shown that immune and 3 
inflammatory mechanisms play a key role in hypertension and its complications. We review 4 
the effects of immunomodulatory interventions on blood pressure, target organ damage and 5 
cardiovascular risk in humans. In experimental and small clinical studies both non-specific 6 
immunomodulatory approaches, such as mycophenolate mofetil and methotrexate, and 7 
medications targeting T and B lymphocytes, such as tacrolimus, cyclosporine, everolimus, 8 
rituximab, lower blood pressure and reduce organ damage. Mechanistically targeted immune 9 
interventions include isolevuglandin (isoLG) scavengers to prevent neo-antigen formation, 10 
co-stimulation blockade (abatacept, belatacept), and anti-cytokine therapies (secukinumab, 11 
tocilizumab, canakinumab, TNF-α inhibitors). In many studies, trial designs have been 12 
complicated by a lack of blood pressure related endpoints, inclusion of largely normotensive 13 
study populations, polypharmacy, and established comorbidities. Among a wide range of 14 
interventions reviewed, TNF-α inhibitors have provided the most robust evidence of blood 15 
pressure lowering. Treatment of periodontitis also appears to deliver non-pharmacological 16 
antihypertensive effects. Evidence of immunomodulatory drugs influencing hypertension-17 
mediated organ damage are discussed. Animal model, observational studies, and trial data in 18 
humans support the therapeutic potential of immune targeted therapies in blood pressure 19 
lowering and in hypertension-mediated organ damage. Targeted studies are now needed to 20 
address their effects on blood pressure in hypertensive individuals. 21 
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In atherosclerosis the role of inflammation is well defined, 1–5 and a co-existing chronic 2 
inflammatory condition such as rheumatoid arthritis, inflammatory bowel disease, ankylosing 3 
spondylitis, and psoriasis is considered an additional risk factor in ESC Cardiovascular 4 
Disease Prevention guidelines. 6–8 Anti-inflammatory therapies are recommended in such 5 
patients, 6 and targeting inflammation to improve cardiovascular outcomes has been 6 
supported by recent clinical trials such as CANTOS, COLCOT, and LoDoCo2. 9–12 7 
Hypertension is the most common cardiovascular risk factor worldwide. 13 For more than half 8 
a century, immune cells have been observed to infiltrate the kidney and vasculature of 9 
hypertensive humans and animals with experimental hypertension, and increasing evidence 10 
indicates that immune and inflammatory mechanisms promote this disease. It is therefore 11 
essential to identify the clinically permissible therapeutic interventions that address 12 
inflammatory targets in hypertension, and patient populations that would benefit from such 13 
treatment. While basic and translational evidence suggests that interfering in immune-14 
inflammatory processes may aid in control of blood pressure (BP) and prevention of target 15 
organ damage,14–16,17 the clinical evidence for these interventions has not been systematically 16 
analysed. Accordingly, we review potential immune therapeutic targets to identify 17 
approaches for which well-designed clinical studies may prove fruitful. 18 
 19 
Immune and inflammatory targets for treatment of hypertension  20 
Inflammation and immune activation were first implicated as being involved in hypertension, 21 
first demonstrated by Grollman, Okuda, Svendsen, 18–21 and Olsen. 22,23 In the last decade new 22 
research has begun to reveal the mechanisms that explain this. 17 Using animal models of 23 
genetic and pharmacological targeting, the regulatory role of T cells, 24–34  cells, 35  24 
monocytes/macrophages, 36–39  dendritic cells, 40 B cells, 41,42 NK cells, 43 as well as other 25 
components of a complex immuno-inflammatory network have been assessed. 17,44–48 The 26 
initiation of inflammation in hypertension appears to be associated with oxidative stress and 27 
redox dependent mechanisms within the vascular and renal tissues. 49,50 These lead to 28 
generation of neo-antigens, 51 damage associated molecular patterns (DAMPs), 52 and 29 
neuroimmune mechanisms 53,54 that trigger maladaptive immune responses 1 which 30 
compound hypertension and its associated organ damage. Although antigen(s) responsible for 31 
activation of adaptive immunity have not been definitively identified, a potential candidate 32 













acid that rapidly ligate lysines on self-proteins and accumulate in antigen presenting cells and 1 
are presented within major histocompatibility complexes. These activate a subset of CD4+ 2 
and CD8+ T cells. Importantly, the selective isoLG scavenger 2-hydroxybenzylamine (2-3 
HOBA) can prevent immune activation and lower BP in several animal models of 4 
hypertension. 51 Data from both animal and human studies also identify HSP70 as a potential 5 
auto-antigen. 55 Numerous animal studies in a wide range of models, reviewed previously, 56–6 
58 highlight that immunomodulation of inflammatory activation and effector cytokine release 7 
may curb BP increases and lessen development of vascular, cardiac, and renal damage. 59–66 8 
Many of these studies have employed germline knockout animals. In addition, small 9 
molecule or neutralizing antibodies that target immune mediators have been used to 10 
determine the effect of selective blockade on experimental hypertension (Table 1). These 11 
have targeted both the innate (e.g. IL-1, TLR4) and adaptive (e.g. IL-17, CD80/86) immune 12 
system. Careful analysis of these studies helps identify potential therapeutic targets, but also 13 
highlights the impact of treatment protocol and animal model selection for BP and target 14 
organ damage outcomes (Table 1; Figure 1).  15 
  16 
Clinical evidence 17 
Epidemiological and observational data from humans support a relationship between the 18 
immune system and hypertension, including the observation that humans with hypertension 19 
are at increased risk of COVID-19 related death.103,104 Inflammatory biomarkers 105–107 20 
correlate with systolic BP (SBP) in acute stroke, each 10 mmHg BP elevation increasing the 21 
odds of an elevated CRP level by 72%. 108 Similarly, observational and clinical trial data 22 
demonstrate BP increases with each CRP quartile. 109,110 A nested case-control study of 400 23 
normotensive women indicated that the risk of developing hypertension during follow up 24 
increases with higher quartiles of IL-6 and CRP. 111 In addition to CRP and IL-6, TNF-α, IL-25 
1β, IL-18 and CCL2 cytokine levels also appear to be increased in hypertension and may 26 
confer risk of developing the disease. 112–118 These cytokines likely promote cell infiltration, 27 
affect renal sodium transport, 75 and alter vascular function and structure, ultimately leading 28 
to sodium and volume retention, increased systemic vascular resistance, and the phenotype of 29 
hypertension.  30 
Circulating leukocytes, which are important cellular components of the immune system, 31 













numbers of circulating leukocytes are associated with hypertension.107 UK Biobank data 1 
similarly indicate that quintile distribution of lymphocyte, monocyte, neutrophil and 2 
eosinophil count is positively associated with BP. 119 Other studies show that an increased 3 
neutrophil to lymphocyte ratio (NLR) predicts development of hypertension. 120–122 4 
Intermediate and non-classical monocytes are associated with inflammatory states and 5 
endothelial dysfunction and are increased in hypertensive patients. 123–125 A recent study has 6 
shown that signals from the activated endothelium in hypertension induces conversion of 7 
classical CD14++/CD16low monocytes to CD14++CD16+ intermediate monocytes. This seems 8 
to be mediated by STAT3 activation and associated with increases in IL-6, IL-1b, IL-23, 9 
CCL-4, and TNF-α. 123 Monocytes from hypertensive patients also express higher TLR4, and 10 
BP control reverses this. 126  11 
A causal role of lymphocytes in human hypertension is supported by large-scale Mendelian 12 
randomisation genetic evidence. 119 T lymphocytes of hypertensive individuals are activated, 13 
with increased IL-17A and IFN-γ production and proportionally higher memory T cells 14 
(CD45RO+) in adults.127 Youn et al have shown that patients with hypertension have an 15 
increased fraction of immunosenescent, proinflammatory, cytotoxic CD8(+) T cells.128 Even 16 
among hypertensive adolescents, a subset of pro-inflammatory CD4+ T cells is associated 17 
with SBP and arterial stiffness. 129 Increased circulating effector memory CD4+/CD8+ T cells 18 
and CD8+CD28null T cells are also present at this early time point in hypertension. 129  19 
In summary, clinical studies identify greater proportions of activated pro-inflammatory 20 
monocytes and lymphocytes in hypertension. This may promote their infiltration into target 21 
organs, leading to perturbations in vascular and renal function, and ultimately modulating BP.  22 
Genetic and multi-omics evidence 23 
Data from Genome-Wide Association Studies (GWAS) and the transcriptome link 24 
hypertension with immune cellular defence and inflammatory responses 130,131. This link is 25 
supported by integrative network analysis 132 and Mendelian randomisation approaches 119, 26 
and is important, considering that heritability of BP is between 33 and 57% 133–135. 27 
Several GWAS have implicated SH2B3/LNK gene in hypertension and myocardial infarction 28 
130,132,136,137. SH2B3 encodes a docking protein that seems to be a modulator of T cell 29 
activation. Variants of this gene are linked to autoimmune diseases such as multiple sclerosis, 30 













profiles from 7,017 individuals not on anti-hypertensive treatment also supports single 1 
nucleotide polymorphism (SNP) rs3184504 in SH2B3 as a trans-regulator of expression of six 2 
out of the 34 BP-related signature genes identified, all of which are expressed in 3 
leukocytes.138 Integrative network analysis of BP GWAS with mRNA expression profiles 4 
from 3,679 participants not on antihypertensive agents confirms molecular interactions 5 
between key drivers such as SH2B3 and hypertension-related genes. 132 Mechanistically, T 6 
cells from LNK knockout mice produce high levels of type I cytokines and these mice exhibit 7 
increased sensitivity to Ang II, leading to hypertension, endothelial and renal dysfunction, 8 
increased inflammatory cell infiltrate and oxidative stress. 139,140 Mendelian randomisation 9 
evidence based on 120 SNPs predictive of leukocyte subpopulations demonstrates a clear, 10 
potentially causal, relationship between lymphocyte count and systolic and diastolic BP, 11 
while BP itself appears to affect monocyte and neutrophil counts. 119 Finally, the recent multi-12 
omic kidney analysis uncovered many immunity-related genes (such as IRF5, IRAK1, BP1, 13 
TRAF1) whose expression, splicing and/or methylation ostensibly demonstrate causal 14 
relationships with BP. 141 15 
 16 
Effects of immunomodulatory drugs on blood pressure 17 
Clinically available immunomodulatory drugs employ heterogeneous mechanisms of action, 18 
and hence their impact on BP regulatory systems is likely to be diverse. Agents reviewed 19 
below are selected to illustrate this breadth.  20 
Selected anti-cytokine therapies  21 
TNF-α inhibitors  22 
Using a systematized search we identified 20 studies reporting BP in patients prescribed 23 
adalimumab, infliximab, etanercept, golimumab, and six papers with a mix of TNF-α 24 
inhibitors used (see Table 2).  Study populations included those with rheumatoid arthritis 25 
(RA), ankylosing spondylitis, psoriasis, and combined rheumatological diseases. Follow up 26 
was from two weeks to twelve months and cohort sizes varied from nine to 5408. Only five 27 
of the twenty studies were randomised and/or placebo controlled. 142–145 Seventeen of these 28 
studies contained data adequate for meta-analysis (Supplementary Methods and Figure 2): the 29 
combined estimate from thirteen studies comparing average BP before and after TNF-α 30 
blockade was a 3.5 mmHg reduction in SBP (95% CI -5.7, -1.3), p=0.001. Five 31 













estimate of 4.1 mmHg SBP lowering (95% CI -7.0,-1.1), p<0.001. Only two studies used the 1 
gold standard of ambulatory BP monitoring (ABPM), Yoshida et al demonstrating a SBP 2 
reduction of 7.3 mmHg. 146 In contrast Grossman et al showed that TNF blockade caused an 3 
increase of 1.7 mmHg. 147 Elevated BP was not an inclusion criterion in any of the studies 4 
and hypertension was reported inconsistently. Two of the studies reported only mean arterial 5 
pressure; 148,149  six studies did not report prevalence or use of anti-hypertensives 145,148,150–153, 6 
one specified no anti-hypertensive use. 154 Hypertension prevalence in the remaining studies 7 
ranged between 7% and 53%. 142–144,146,147,155–160 In some studies, good BP control was an 8 
inclusion criteria. 147,155–157 Finally, individual level data was not available, thus any effect in 9 
hypertensive participants may be masked through reporting of average BP across whole study 10 
cohorts, though despite this, combined estimates from observational and randomised trials do 11 
suggest a BP lowering effect of anti-TNF-α agents (Figure 2). Observational data on incident 12 
rates of hypertension offer additional insight. In comparison with non-biologic anti-13 
inflammatory medications, 4822 anti-TNF-α initiators demonstrated no difference in crude or 14 
adjusted rates of incident hypertension (HR 0.95, 95% CI 0.74-1.2),161 results supported by a 15 
smaller Korean cohort of 996 patients with RA.162 Paradoxically, previous meta-analysis 16 
suggested higher rates of incident hypertension as adverse events in TNF-α inhibitor 17 
recipients (OR 1.89, 95% CI 1.35-2.65). 169 This disparity indicates need for targeted studies 18 
in hypertensive populations. 19 
 20 
IL-1 inhibition (CANTOS trial) 21 
In a large RCT of patients with prior myocardial infarction and elevated hsCRP, the IL-1β 22 
antagonist canakinumab 150 mg demonstrated benefit versus placebo for a composite end 23 
point of myocardial infarction, stroke or cardiovascular death. Largest effect size was in the 24 
quartile demonstrating greatest hsCRP and IL-6 reductions.10,166  Rates of incident 25 
hypertension however did not differ by hsCRP tertiles; nor did canakinumab demonstrate a 26 
reduction in incident hypertension (HR 0.96 [0.85–1.08], P>0.2). Ostensibly this suggests 27 
that BP may not be the mechanism by which benefit was exerted, however baseline 28 
prevalence of hypertension was 80%, thus only 20% of participants were ‘at risk’ from 29 
incident hypertension. 167 In the canukinumab arm, only subgroups with baseline BP (SBP 30 
≥130 mm Hg) demonstrated BP lowering, as well as protection from major adverse cardiac 31 
events (MACE). 167 Fatal infections were increased with canukinumab, highlighting the 32 














Considering other cytokine inhibitor approaches, we focused on pharmacotherapies with both 2 
animal study evidence and use in clinical practice: secukinumab and tocilizumab. We 3 
identified the FIXTURE trial of IL-17 antagonist secukinumab (150 mg and 300 mg groups) 4 
in patients with psoriasis. Despite BP being the primary outcome, this trial reported no 5 
change at one year, though patients were not hypertensive at baseline. 145 In contrast, a study 6 
of 50 patients with psoriasis commenced on secukinumab demonstrated a 6 mmHg reduction 7 
of SBP (130mmHg to 124 mmHg, P=0.3). 168 This is particularly important as psoriasis, like 8 
RA, appears to be associated with increased prevalence of hypertension and cardiovascular 9 
disease. 169–171 10 
Anti-IL-6 11 
Three papers were identified reporting BP data with IL-6 antagonist tocilizumab, two used in 12 
combination with methotrexate. 172,173 SBP increase was demonstrated by Elmedany et al. 13 
(116±16 vs 129+/-17 mmHg, p=0.001), 172 the other two papers reporting no change in BP 14 
with IL6 blockade173,174, though the average baseline BP values were normal range. Overall, 15 
the minimally available evidence (detailed in Supplementary Table) does not support an 16 
association with BP lowering. 17 
Immunosuppressant Agents 18 
Mycophenolate mofetil (MMF) 19 
MMF inhibits nucleotide synthesis and thus prevents lymphocyte proliferation. In an early 20 
study, Herrera et al. demonstrated a reduction in average BP from 152/92 to 137/83 mmHg at 21 
12 weeks in eight patients with psoriasis. Notably, BP increased following MMF cessation in 22 
this study. The authors also demonstrated a reduction in urinary TNF-α was during MMF 23 
therapy.175 Other studies reporting BP data are confounded by the presence of nephropathy, 24 
with concomitant anti-hypertensive treatment to achieve target BP under 130/80 mmHg, or 25 
organ transplantation in which improvement in volume status could obscure any independent 26 
impact of MMF on BP. With these caveats in mind, two trials of MMF in IgA nephropathy 27 
report BP reduction of -7 to -14 mmHg.176,177 In two other studies of patients with lower 28 
enrolment BP, MMF did not reduce SBP beyond treatment with angiotensin-converting 29 
enzyme inhibitors (ACEi) alone, or ACEi plus placebo. 178,179 Head-to-head trials in 30 
transplantation showed that treatment with tacrolimus/MMF lowered SBP by 4 mmHg (p= 31 













receiving tacrolimus/sirolimus. Ninety percent of these subjects had hypertension at 1 
baseline.180 In a smaller study, no change in BP occurred in 58 liver transplant patients 2 
treated with a tacrolimus/MMF (p=0.88, baseline average 129/70 mmHg) whilst a group 3 
treated with tacrolimus/steroid showed an 8 mmHg rise in SBP. 181 Overall, the clinical 4 
evidence favours association of MMF with BP reduction in hypertension (see Figure 3), 5 
however, no data specifically pertaining to hypertensive patients are available. 6 
Methotrexate  7 
Methotrexate is a chemotherapy agent and DMARD. Five studies involving between 20 and 8 
8065 participants were identified, reporting average baseline SBP between 121 and 137.5 9 
mmHg. Only one of these employed ABPM. Average SBP lowering ranged from 1.4 to 5.9 10 
mmHg, and DBP reduction of up to 4.4 mmHg (see Supplementary Table, Figure 3). 11 
143,159,164,182,183 Conversely, Makavos et al 168 and CIRT 184 RCTs in psoriasis and patients 12 
with established cardiovascular risk respectively, did not demonstrate average BP reduction 13 
with methotrexate. Considering the discrepancy, although 90% of the CIRT cohort had 14 
hypertension diagnoses, baseline BP values were not reported, precluding assessment of BP 15 
effects in individuals with uncontrolled hypertension. 16 
Hydroxychloroquine 17 
Hydroxychloroquine is an antimalarial agent that is used as a DMARD, and experimentally in 18 
IgA nephropathy 159,164,185 This agent has been shown to reduce circulating DCs and reduces 19 
IFN-, IL6, and TNF-α levels. 186 Three studies of hydroxychloroquine have demonstrated 20 
BP lowering. The largest of these involved 7147 patients with RA and showed that 21 
hydroxychloroquine lowered BP by 1.2 mmHg systolic / 0.6 mmHg diastolic from a baseline 22 
of 130/75 mmHg at 6 months.159 Two smaller studies report SBP lowering of 3 to 8.8 mmHg 23 
(see Supplementary Table). 24 
Leflunomide 25 
Leflunomide is a pyrimidine synthesis inhibitor used in active RA and psoriatic arthritis. In 26 
three studies, in which the subjects had an average baseline SBP ranging from 128 to 133 27 
mmHg, a small increase of 1.44 to 4.3 mmHg systolic and 0.57 to 4.8 mmHg diastolic in 28 
office and ambulatory BP was observed. 159,164,187  29 
Calcineurin inhibitors (CNIs) 30 
CNIs block the earliest steps of T cell activation, but also have substantial off target effects, 31 













vasoconstriction, salt retention and hypertension (Figure 4).188,189 Eight studies with BP data 1 
following 12 to 36 months of CNI treatment are reviewed (see Supplement).  In four of these 2 
the baseline BP was in the hypertensive range. 190–193 Six reported lowering of BP (range -1 3 
to -13 mmHg),190–195 while two demonstrated a rise in BP of 5 to 11 mmHg. 168,196 Further 4 
detail is available in the Supplement and reviewed elsewhere, 189 but in summary, limitations 5 
of trial design, and CNI off target effects make interpretation of BP effects of CNIs difficult 6 
(Figure 4). 7 
mTOR inhibitors 8 
mTOR inhibitors such as sirolimus and everolimus regulate cellular metabolism, growth, and 9 
proliferation, offering alternative immunosuppression following transplantation. Of six 10 
studies we found reporting BP values, the three reporting an average baseline SBP >140 11 
mmHg all suggested a reduction in BP of between 3 and 8 mmHg 190,191,193, though only one 12 
achieved statistical significance 190. ABPM was only measured in the SCHEDULE trial of 13 
heart transplant patients treated with everolimus. An 8 mmHg fall in SBP (p=0.05), and no 14 
change in DBP occurred from two weeks post-transplant to twelve months follow up. This 15 
was dominated by reduction in nocturnal SBP in both the everolimus and cyclosporine 16 
arms.190 BP lowering was not observed when the average baseline BP for the study was in the 17 
normotensive range. 196 mTOR inhibitors in comparison with other agents reported SBP 18 
outcomes that were neutral or elevated (0 or +4 mmHg change). 180,196,197 These studies are 19 
complicated by the concomitant use of multiple other drugs (see Supplement). 20 
CTLA-4-Ig 21 
Abatacept is composed of the Fc region of the immunoglobulin IgG1 fused to the 22 
extracellular domain of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). This agent 23 
targets T cell co-stimulation and is commonly used in transplant and rheumatologic diseases. 24 
In five studies of RA patients reporting BP outcomes with abatacept, specific values were not 25 
available for two and none of the others reported a statistically significant effect on BP. 26 
172,174,198–200 Seven studies reporting BP outcomes using Belatacept, an alternative CTLA-Ig, 27 
were identified. All of these were in transplant recipients and were compared to patients 28 
receiving CNIs. Two of these studies involved cross over from CNI to Betlatacept and 29 
showed a SBP reduction of 5.4 and 8.8 mmHg (p=0.38 and 0.03 respectively).201,202 A case-30 
control study reported a 9 mmHg lower SBP in subjects treated with this agent (p=0.68)203. 31 
Three RCTs showed a reduction in SBP between -2.4 and -9 mmHg204–206, but only one of 32 













difference in mean SBP 207. In only two studies did the subjects have an average baseline 1 
SBP in the hypertensive range,200,202 and no studies employed ABPM. The apparent BP 2 
benefit with belatacept but not abatacept likely reflects population differences (transplant 3 
versus RA respectively), potential physiological changes post-transplantation, and the cross-4 
over effect from CNI, which as noted above, has off-target effects that can raise BP. 5 
Rituximab 6 
Rituximab is a monoclonal antibody against CD20, resulting in B cell apoptosis and 7 
depletion. It is used in lymphoid and blood malignancies and diverse autoimmune diseases. 8 
Trials reporting BP that are not confounded by polypharmacy were sparse. We identified four 9 
such studies, and none involved patient groups with uncontrolled hypertension – the average 10 
participant baseline SBP being 131/83mmHg or lower. 174,208–210 An early reduction in BP is 11 
common, but data reporting longer-term trends were discordant. No BP effect was seen in RA 12 
174,208,209; but a BP reduction was observed in membranous nephropathy at 4 weeks, though 13 
not sustained to 20 weeks. 210 14 
 15 
 Determinants of the blood pressure effects of immunosuppressants 16 
In summary, trials in rheumatic, autoimmune, and transplant patients indicate a possible BP 17 
lowering effect of selected anti-inflammatory therapies targeting diverse pathways previously 18 
identified by pre-clinical studies. The evidence appears to be most consistent in relation to 19 
anti-TNF agents, while other therapies such as hydroxychloroquine, MMF, and mTORs all 20 
suggest BP lowering effect (Figures 3 and 5). Data are however conflicting, and hypertension 21 
was rarely a pre-specified outcome measure. Trials often involved normotensive populations 22 
in which BP lowering is difficult to observe. A combined analysis of studies discussed in this 23 
paper shows that cohorts with higher average baseline SBP appear to achieve greater BP 24 
lowering effect (Figure 3), an association also reported for antihypertensive drugs.211–213 25 
These effects are also likely to be influenced by a natural regression a mean value during 26 
observation. 27 
 28 
Non-pharmacological interventions 29 
Several non-pharmacological treatment approaches have shown beneficial effects in reducing 30 
inflammation and therefore improving patient outcomes in the context of hypertension.  31 













Animal studies suggest that periodontal Porphyromonas gingavalis infection increases INF-Ɣ 1 
and TNF- production through modulation of Th1 responses, leading to BP elevation, 2 
endothelial dysfunction and vascular inflammation.214 This link is supported by Mendelian 3 
randomization 215, observational data, and meta-analysis.216–219 Data from well controlled 4 
trials demonstrate that intense treatment of periodontitis can improve endothelial function,220 5 
lower inflammatory markers and BP as measured by ABPM, with a mean baseline of 135/84 6 
mmHg and change of –7.5 mmHg (P<0.001).221  A meta-analysis of eight studies involving 7 
intensive periodontal treatment  showed an average decrease of SBP of −4.3 mm Hg (95% CI 8 
−9.1–0.5) and DBP −3.16 mm Hg (95% CI −6.5–0.2), though none of these achieved 9 
statistical significance. As in the case of pharmacological interventions, BP reductions were 10 
not observed in normotensive individuals. 222 11 
 12 
Energy metabolism, microbiome, and salt 13 
Physical activity has an established role in BP regulation, with three months of exercise 14 
lowering SBP by approximately 5 mmHg and DBP by 3 mmHg. 223 Physical activity also has 15 
demonstrable immune effects.224 Exercise can both increase circulating numbers of T cells 16 
225, and improve response to influenza vaccination.226 17 
For dietary interventions, most research has focussed on CVD risk reduction, though BP 18 
lowering has also been demonstrated in both normotensive and hypertensive cohorts 227,228,  19 
at least in part immune-mediated via effects of diet on the microbiome.229 Metagenome-wide 20 
association evidence of gut dysbiosis in hypertension includes restricted sample diversity, 21 
higher lipopolysaccharide synthesis, membrane transport, and steroid degradation; suggesting 22 
low grade inflammatory stimuli may be the mechanism. 230 Evidence is accumulating that 23 
plant-based dietary protein may promote bacterial species associated with anti-inflammatory 24 
effects while meat consumption is linked to CVD and inflammatory bowel disease. 231 25 
Dietary salt is another dominant driver of hypertension, primarily through activation of 26 
RAAS232;  at higher concentration, salt also favours pro-inflammatory monocyte 233 and T 27 
cell phenotypes with increased tissue infiltration 234 and microvascular dysfunction. 235 28 
Highly controlled experimental reduction in salt intake lowers pro-inflammatory IL-6 and IL-29 
23, and increases IL-10 levels, 236 though this effect was not detected in a larger observational 30 
study. 237   31 













The central nervous system (CNS) regulates vascular and kidney function through 1 
sympathetic innervation but is also a potent modulator of immune responses. Animal and 2 
human studies demonstrate the role of neuroimmune axis in the pathogenesis of hypertension. 3 
238,239,  with murine renal denervation (RDN) inducing a reduction in BP, 240–243 and reduction 4 
in renal inflammation, T cell activation, and pro-inflammatory cytokine production. 241,244  5 
However, SIMPLICITY, SPYRAL, and RADIANCE human clinical trials demonstrate 6 
inconsistent results, mostly favouring sustained BP reduction. 245,246 Some but not all 247 of 7 
these were sham-controlled RDN designs. 248–250 The effect of renal denervation on immune 8 
activation in humans is less clear. One trial demonstrated reductions in TNF-α and IL-1 and 9 
upregulation of IL-10 one day after RDN, however this did not persist to day three 251, and 10 
was not corroborated elsewhere. 252,253  11 
An alternative approach to sympathetic denervation is augmentation of parasympathetic 12 
activity through vagus nerve stimulation (VNS). This approach has proven effective in 13 
hypertensive rodent models. 254–256  VNS limits hypertension-induced endothelial dysfunction 14 
257 and reduces levels of systemic cytokines and mRNA expression in target organs, 258 with 15 
both afferent and efferent VNS protecting mice from kidney injury. 259 Anti-inflammatory 16 
effects of VNS are abolished in immune-deficient 266 and β2 adrenergic receptor-deficient 17 
mice.261  When stimulated by Ang II or bioelectronic signals, a splenic neuroimmune cascade 18 
is triggered via -adrenergic receptors. In response, CD8+ effector T cells with a role in 19 
hypertension 25 egress from the spleen. 262 VNS has not yet been tested in human 20 
hypertension, but has been used in epilepsy and in RA, demonstrating lowering of circulating 21 
TNF, IL-1β, and IL-6 levels and improvement in disease activity.263  22 
 23 
Hypertension-mediated organ damage (HMOD) 24 
HMOD correlates with BP values in hypertension,264,265 however, genetics, lifestyle, and co-25 
morbid conditions may also contribute to end-organ damage independently of BP levels. 26 
Similarly, the target organ benefit of immunomodulation might be partially independent of 27 
BP effects. The strength of evidence regarding the effects of immunomodulatory therapy on 28 
HMOD in experimental and clinical settings is summarized in Figure 5. Registry data of 29 
active RA, with 30% hypertension prevalence, suggested no difference in myocardial 30 
infarction rates in response to TNF-α inhibitors versus DMARDs. However, 60% fewer 31 
events did occur in the TNF-α inhibitor responder subgroup versus non-responders. 266 The 32 













was adjusted for traditional risk factors. This study reported a reduction in cardiovascular risk 1 
in response to numerous immunomodulatory drugs, including biologic agents (HR 0.42; 95% 2 
CI 0.21 to 0.81), methotrexate (HR 0.85; 95% CI 0.81 to 0.89), sulfasalazine (HR 0.92; 95% 3 
CI 0.87 to 0.98), and leflunomide (HR 0.59; 95% CI 0.43 to 0.79); P<0.05. 267 Baseline BP 4 
values were not reported in either paper. Nurmohamed et al. reviewed 90 studies reporting 5 
cardiovascular risk outcomes in rheumatological conditions treated with abatacept, TNF-α 6 
inhibitors, rituximab, secukinumab, tocilizumab and tofacitinib. They report a neutral effect 7 
on BP, on surrogate markers of cardiovascular risk, and on MACE, though authors emphasise 8 
the variation in quantity and quality of evidence. 268 9 
Observational data based on 13,000 matched pairs from Medicare and MarketScan patients 10 
with RA and newly treated with abatacept or a TNF-α inhibitor found benefit of abatacept in 11 
MACE restricted to the subgroup with diabetes (HR of 0.74 [95% CI, 0.57–0.96]). 269 12 
Potential confounding arose from higher rates of hypertension in the diabetic subgroups, 13 
again supporting potential benefit of TNF-α inhibitors in hypertension. 167 Finally, a meta-14 
analysis of 14 studies in patients with RA, adjusted for hypertension, concluded that 15 
DMARDs were associated with an increased risk of MACE relative to TNF-α inhibitor 16 
therapy (OR 1.58 [95% CI 1.16–2.15]; I2=16%), effect maintained in presence or absence of 17 
MTX. 270  18 
Colchicine is hypothesised to inhibit microtubular polymerization, assembly of the NLRP3 19 
inflammasome, and IL-1β and IL-18 production. In acute coronary syndrome colchicine 20 
abrogates local increases in IL-1β, IL-18, and IL-6 levels, 271 and its’ addition to aspirin and 21 
statin reduces hsCRP. 272  Colchicine 0.5 mg daily has been demonstrated to reduce MACE 22 
by 67% compared to placebo in LoDoCo RCT of 532 patients with stable coronary artery 23 
disease 273, though the similarly sized COPS trial found no benefit in cardiovascular 24 
outcomes. 274 The larger COLCOT trial of 4745 participants recruited within 30 days of acute 25 
coronary syndrome reported composite cardiovascular end-point occurrences in 5.5% of the 26 
colchicine group, versus 7.1% of the placebo group (HR 0.77; 95% CI 0.61 to 0.96; P=0.02). 27 
9  Half of these patients had hypertension. Similarly, LoDoCo2 randomised 5522 chronic 28 
coronary disease patients to low-dose colchicine, with composite end-point events in 29 
6.8% of the colchicine group, versus 9.6% of placebo group (HR 0.69; 95% CI 0.57 to 0.83; 30 
P<0.001). 11   31 
Overall, we would conclude that there is evidence of improvement in MACE for TNF-α 32 
inhibitors, MTX, tocilizumab, secukinumab, leflunamide and colchicine, though 33 













have not explored the relationship between reduction in inflammation and MACE suggested 1 
by CANTOS and TNF-α inhibitor responders in the registry data above 5,226. HMOD 2 
outcomes beyond MACE are surmised in Figure 5 for common immunomodulatory drugs.  3 
 4 
Conclusions 5 
While experimental, genetic, and clinical evidence supports the role of inflammation and 6 
immune system involvement in hypertension and associated vascular, renal, and cardiac 7 
pathology, immunomodulatory approaches are not currently considered therapeutic options in 8 
BP lowering and cardiovascular disease reduction. Indeed, clinical evidence reviewed in this 9 
paper shown a highly heterogeneous effect of immune targeting on BP and cardiovascular 10 
events across a wide range of patients mainly with various underlying immune mediated 11 
diseases. Going forward there are several important considerations. As is the case with 12 
traditional anti-hypertensive medications the BP lowering effects of anti-inflammatory agents 13 
appear to be limited to those with uncontrolled hypertension. This is not surprising as 14 
numerous compensatory mechanisms make lowering beyond normal BP difficult. It is also 15 
important to consider that the effects may be limited to patients with active pro-hypertensive 16 
inflammatory mechanisms. The lesson from CIRT, TNF-α inhibitor responders vs non-17 
responders, CANTOS, and the body of the evidence presented, is that there must be active 18 
inflammation. Hence, cardiovascular risk reduction with immune modulation is mediated not 19 
through BP alone, but via broader mechanisms of oxidative stress, endothelial function, 20 
vascular remodelling, and endocrine regulation, that are the ‘common denominators’ of a 21 
dysfunctional relationship. Secondly, we must target the optimal checkpoint in the 22 
inflammation-hypertension relationship to optimise benefit without adverse effect, and so far, 23 
this has remained elusive at a population level. Finally, it is important to consider that 24 
virtually all of the preclinical studies investigating the anti-hypertensive effect of immune 25 
interventions on hypertension have involved treatment of animals at the onset on 26 
hypertension, often concomitantly with the onset of the disease. In contrast, these agents are 27 
usually given to humans with long-standing hypertension. It is possible, and even likely that 28 
once hypertension has been established, there are chronic changes in renal and vascular 29 
function and structure that render such treatment less effective. In this regard, treatment of 30 
younger individuals with early onset hypertension might yield different results than those 31 
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Figure 1. Animal model evidence of mechanisms by which the innate and adaptive immune 1 
system regulate blood pressure through effects on the kidneys, heart, and vasculature.   2 
Legend: CD, cluster of differentiation; CCR, chemokine receptor; Treg, T-regulatory cell; 3 
TH, T-helper cell; IL, interleukin; TNF-α, tumour necrosis factor alfa; NH-B, Nuclear factor 4 
kappa B; IFNinterferon NLPR3, NOD-like receptor family, pyrin domain-containing 5 
protein 3; TGF-, transforming growth factor beta; TLR, Toll-like receptor; PEG-sTNFR1, 6 
pegylated  soluble tumour necrosis factor receptor 1; TAK-242, inhibitor of TLR4 7 
signalling; 2-HOBA, 2-hydroxybenzylamine; MCC950, small-molecule inhibitor of the 8 
NLRP3 pathway; INCB3344, CCR2 antagonist; Met-RANTES, CCR5 antagonist.  9 
  10 
Figure 2. Meta-analysis and Forest Plot using random effect model, of TNF-α inhibitor 11 
studies reporting SBP outcomes, with reference to average baseline SBP, population size, and 12 
study weighting.  13 
Legend: ADL, Adalimumab, ETN, Etanercept, GOL, Golimumab, IFX, Infliximab, Mixed, 14 
different TNF-α inhibitors within the study; SBP, systolic blood pressure; sDMARD, 15 
conventional synthetic disease modifying anti-rheumatic; TNF-α, tumour necrosis factor alfa. 16 
Effect size reports average change in SBP in mmHg; * indicates ambulatory BP monitoring 17 
and MAP indicates only mean arterial pressure data available. Panel A includes cohort 18 
studies reporting average SBP prior and subsequent to drug initiation; panel B includes 19 
randomised trials with comparison to placebo or other pharmacotherapy. Overall change in 20 
average SBP accompanied by 95% confidence interval (black) and prediction interval 21 
(green). 22 
 23 
Figure 3. Panel A: Bubble plot illustrating immunomodulatory agents plotted by baseline 24 
SBP (x-axis) and average change in SBP (y-axis), both in mmHg, with 25 
bubble area representing cohort size. Panel B: Scatterplot of average change in SBP by 26 
average baseline SBP, with R2 = 31%.  27 
Legend: CNI, calcineurin inhibitor; CTLA4-Ig, cytotoxic T-lymphocyte-associated protein 4 28 
immunoglobulin; HCQ, hydroxychloroquine; IL, interleukin; MMF, mycophenolate mofetil; 29 













TNF, tumour necrosis factor. Both panels: red box illustrates cohorts with average baseline 1 
SBP in hypertensive range.  2 
 3 
Figure 4. Renal and immune system effects of calcineurin inhibitors influencing blood 4 
pressure. 5 
Legend: COX2, cyclooxygenase-2; GFR, glomerulofiltration rate; IL-2, interleukin-2; 6 
NFAT, nuclear factor of activated T cells; NO, nitric oxide; TMA, thrombotic 7 
microangiopathy; RAAS, renin-angiotensin-aldosterone system; ROS, reactive oxygen 8 
species; SNS, sympathetic nervous system; TGF-, transforming growth factor beta. Created 9 
in BioRender. 10 
 11 
Figure 5. Immunomodulatory drugs and the level of animal and clinical evidence available 12 
regarding blood pressure and organ system outcomes. Summarised according to the 13 
aggregated weight of the available evidence. 14 
Legend: * Includes cardiovascular outcomes. ^ Includes cerebrovascular, PAD, arterial 15 
stiffness, and endothelial function outcomes. # Includes chronic kidney disease, end-stage 16 
kidney disease, fibrosis, and inflammation. BP, blood pressure; CD, cluster of differentiation; 17 
CNI, calcineurin inhibitor; CTLA4-Ig, cytotoxic T-lymphocyte-associated protein 4 18 
immunoglobulin; HCQ, hydroxychloroquine; IL, interleukin; MMF, mycophenolate mofetil; 19 
mTOR: mammalian target of rapamycin; MTX: methotrexate; TNF, tumour necrosis factor. 20 
 21 
Table 1. Key findings relevant to the relationship between the immune system and 22 
hypertension arising from animal models. 23 
Legend: Ab, antibody; ang-II, angiotensin II; BP, blood pressure; CCR, CC motif chemokine 24 
receptor; CD, cluster of differentiation; CNI, calcineurin inhibitor; CTLA4-Ig, cytotoxic T-25 
lymphocyte-associated protein 4 immunoglobulin; DOCA, deoxycorticosterone acetate; 26 
dTGR, double transgenic rats; IL, interleukin; IFNinterferon IMPDH, Inosine-5′-27 
monophosphate dehydrogenase; mTOR: mammalian target of rapamycin; MTX: 28 
methotrexate; NF-b, nuclear factor kappa b; NLRP3, NOD-like receptor family pyrin 29 













rat; SLE, systemic lupus erythematosus; TGF-, transforming growth factor beta; TLR, Toll-1 
like receptor; TNF, tumour necrosis factor.  2 
 3 
Table 2. Human studies pertaining to TNF-α inhibitor use and reporting data on BP 4 
outcomes.  5 
Legend: ADL Adalimumab, ank spod, ankylosing spondylitis; IFX Infliximab, ETN 6 
Etanercept, GOL Golimumab. MAP: mean arterial pressure; PsA, psoriatic arthritis; RA, 7 
































Table 1. Key findings relevant to the relationship between the immune system and 1 
hypertension arising from animal models. 2 
Immune target and 
therapeutic agent 








































Mice infused with ang-II for 14 days 
 
 
Spontaneously hypertensive dTGR rats  
 
 
Dahl salt-sensitive rat with renal 
interstitial administration of etanercept 
 
 




Mouse model of SLE 
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failure in rats 
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treated with DOCA-salt up to 28 days 
 
 BP 
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cardiac inflammation and 
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overexpression of mineralocorticoid 
 



























receptor  (TMROV mice) treated with 
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136 ± 17.8 -9.1 (-20,2) 
P=0.1 
9/34 had controlled HTN. Other 
DMARDs/anti-hypertensives permitted, 
but no alterations to concomitant 










119 ±9.9 -9 (-14, -4) 
P=0.001 
No antihypertensive use. 
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P=0.007 














Age 55 N=17 
12 wks 
Control group (stable on DMARD): no 





N=16 (10 F) 
RA 
Age 57 
Pre-/post- IFX ± 
MTX 
2 wks 
127.4±21.8 -7.3 (-10, -4) 
P<0.001 
24hr BP. 7/16 HTN; no hypotensive drug 
administered during study. 















-5 (-13, 3) 
P=0.22 
-9 (-18, 0)  
P=0.06 
7/26 controlled HTN. 
Comparator group on MTX showed no 













136 ±20 -4.8 (-8, -2)* 
P=0.001 
7% of IFX group on anti-hypertensive. 
* Adjusted for Δ DAS, baseline SBP, age, 
gender, antihypertensive use and Δ BMI. 
DAS >2.4 associated with higher BP. 
BP reduction in IFX responders –6.8, non-















130 ± 24 
-4.2 ± 13.4 
P value not 
reported 
-3 ± 15 
P=0.78* 
6/20 HTN. Steroids and other DMARD 
use permitted. 









124 ±15 -3.1 (-22, 
16) 
P=0.55 
5/28 controlled HTN.  
89% on other sDMARDs. 
























Pre-/post- ADL ± 
DMARD 
16 wks 
130 ±30 -2 (-7, 3) 
P=0.44 
46/171 HTN 














-2 (-5, 1) 
P=0.2 
Rates of baseline HTN/BP medications 
unknown. 
















53% of whole cohort (90/169) had HTN, 


















N=17 (9 F) 







-1.2 (-4, 2) 
P=0.37 
2/17 HTN (BP had to be well controlled 
for 6 months). 










P value not 
reported 
Rates of baseline HTN/BP medications 
unknown. Secukinumab and placebo arms, 










131 ±16 -0.6 (-19,18) 
P value not 
reported 
Data derived from administrative database. 






N=17 (11 F) 
RA 
Age 58 

























7/20 concomitant MTX or sulfasalazine 














1.7 (-22, 25) 
P=0.88 
ABPM. 
2/15 HTN: included if stable for 3 months 
and BP controlled. 












140 ±6 4 (-4,12) 
P=0.3 
Rates of baseline HTN and BP 
medications not reported. 
Concurrent DMARD use (MTX 11/14, 
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